Captor Therapeutics Nominated for the Prestigious
Prix Galien USA 2026 Award in the “Best Startup” Category
WROCŁAW, Poland / ALLSCHWIL, Switzerland, August 13, 2026 – Captor Therapeutics S.A., a leading biopharmaceutical company focused on the development of breakthrough therapies based on targeted protein degradation (TPD), is honored to announce that it has been nominated for the Prix Galien USA 2026 Award in the “Best Startup” category. The winners will be announced during the Prix Galien USA Awards ceremony, which will take place on October 29, 2026, at the American Museum of Natural History in New York City.
The Prix Galien Awards, often referred to as the biopharmaceutical equivalent of the Nobel Prize, are awarded by The Galien Foundation – a leading global institution recognizing innovators in the life sciences sector. The nomination for Captor Therapeutics is a testament to the company's innovative approach and its immense potential to create therapies that can make a real impact on improving patient health and lives.
This year, the “Best Startup” category enjoyed unprecedented interest. The Foundation received a record number of over 250 submissions, from which, after a rigorous evaluation process, only 84 nominees were selected. In accordance with the nominating committee's guidelines, candidates are evaluated solely on Science and Health Impact, rather than sales performance.
"Being named among the nominees for the Prix Galien Award is a tremendous honor for the entire Captor Therapeutics team, as well as for Polish biotechnology. It is also a confirmation of the highest quality of our scientific research and another international recognition of Captor's achievements, following the 'Drug Hunter - Molecule of the Month' distinction," said Michał Walczak, CEO/CSO. "This recognition motivates us to continue our work on developing degraders for the most challenging molecular targets and the most devastating diseases."
This year's edition of the awards holds special significance as The Galien Foundation celebrates the 20th anniversary of honoring digital breakthroughs, pioneering startups, and ecosystems driving the future of healthcare.
"Witnessing the incredible momentum in medical technology, digital health, and startup ventures is inspiring," said Kenneth C. Frazier, Co-Chair of the Galien Forum, Prix Galien USA Awards Committee. "As we celebrate two decades of the Prix Galien USA Awards, we look forward to honoring this new class of nominees whose inventive work epitomizes the future of health and our collective commitment to improving lives through scientific brilliance."
Bruno Cohen, Chairman of The Galien Foundation, added: "We applaud this year's remarkable Prix Galien USA nominees as we mark twenty years of excellence in medical technology, digital health, and entrepreneurship. Their achievements beautifully demonstrate how scientific advancements can transform human lives and improve the wellbeing of our planet."
About the Prix Galien Award and The Galien Foundation
The Prix Galien Award, recognized as one of the highest honors in the pharmaceutical and biomedical industry, honors outstanding achievements in advancing medicine and medical technologies. The Galien Foundation supports and promotes innovations aimed at improving global human health, inspiring collaboration between science and industry leaders.
Prix Galien Press Release: [LINK]
CAPTOR THERAPEUTICS
Captor Therapeutics is a biopharmaceutical company specializing in the development of breakthrough drugs based on Targeted Protein Degradation (TPD) technology for the treatment of diseases with high unmet medical needs. TPD enables an innovative approach to drug discovery that can target novel molecular targets previously considered undruggable using conventional drug development methods, providing new therapeutic options for diseases where existing medications do not offer optimal benefits. Currently, Captor is developing drugs for severe, incurable diseases, including malignant tumors and autoimmune disorders.
For more information about Captor Therapeutics, please visit:
Website: http://www.captortherapeutics.com
LinkedIn: @CaptorTherapeutics
